26 citations
,
November 2016 in “European Journal of Clinical Pharmacology” This study found that using valproic acid during radiotherapy for glioma was associated with delayed hair loss and improved survival outcomes.
4 citations
,
July 2021 in “Cancer Research and Treatment” This study found that adding concurrent and adjuvant temozolomide to radiotherapy for patients with anaplastic gliomas improved progression-free survival without adversely affecting health-related quality of life.
32 citations
,
August 2020 in “American Journal Of Pathology” This study reports that in ovarian high-grade serous carcinoma, overexpressed S100A4 likely promotes epithelial-mesenchymal transition and cancer stem cell properties, affecting tumor behavior through its interaction with NMIIA and mutant p53.
1 citations
,
November 2025 in “Neuro-Oncology” In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.
15 citations
,
November 2022 in “Cell Death and Disease” In this study, the researchers identified CEP135 as a biomarker linked to poor sarcoma survival and suggested PLK1 as a potential therapeutic target for sarcoma patients with high CEP135 expression.